Of clinical significance, Mer expression dictates the sensitivity of NSCLC cells harboring EGFR mutation to EGFR-targeted agent erlotinib, providing a rationale to develop clinically translatable compounds inhibiting Mer as potential therapeutics to overcome the erlotinib resistance. This evidence concerns the gene EGFR and non-small cell lung carcinoma.